271 related articles for article (PubMed ID: 25039358)
1. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
3. Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
Han J; Sun LD; Qian H; Huang WL
Chin J Nat Med; 2014 Aug; 12(8):613-8. PubMed ID: 25156287
[TBL] [Abstract][Full Text] [Related]
4. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
Han J; Sun L; Chu Y; Li Z; Huang D; Zhu X; Qian H; Huang W
J Med Chem; 2013 Dec; 56(24):9955-68. PubMed ID: 24308627
[TBL] [Abstract][Full Text] [Related]
6. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity.
Han J; Huang X; Sun L; Li Z; Qian H; Huang W
Biochem Pharmacol; 2013 Jul; 86(2):297-308. PubMed ID: 23707756
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
9. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
10. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
[TBL] [Abstract][Full Text] [Related]
11. Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities.
Han J; Fei Y; Zhou F; Chen X; Zhang Y; Liu L; Fu J
Br J Pharmacol; 2018 Feb; 175(3):544-557. PubMed ID: 29171021
[TBL] [Abstract][Full Text] [Related]
12. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Han J; Fu J; Yang Q; Zhou F; Chen X; Li C; Yin J
Eur J Med Chem; 2020 Jul; 198():112389. PubMed ID: 32388115
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
14. Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
Cai X; Sun L; Dai Y; Avraham Y; Liu C; Han J; Liu Y; Feng D; Huang W; Qian H
Bioorg Med Chem; 2018 May; 26(9):2599-2609. PubMed ID: 29673717
[TBL] [Abstract][Full Text] [Related]
15. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
[TBL] [Abstract][Full Text] [Related]
16. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Irwin N; Flatt PR; Patterson S; Green BD
Eur J Pharmacol; 2010 Feb; 628(1-3):268-73. PubMed ID: 19917278
[TBL] [Abstract][Full Text] [Related]
17. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
[TBL] [Abstract][Full Text] [Related]
18. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
19. Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.
Sisley S; Smith K; Sandoval DA; Seeley RJ
Peptides; 2014 Aug; 58():1-6. PubMed ID: 24879927
[TBL] [Abstract][Full Text] [Related]
20. Albumin-binding domain extends half-life of glucagon-like peptide-1.
Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
